Antares Vision
Living technology
for a healthier and a safer world
Decommissioning
Ready to Market: New Solution for Decommissioning from Antares Vision
Within the framework of the EU Falsified Medicines Directive – coming into force on February 9, 2019 – all operators involved with pharmaceuticals distribution must connect to the Medicine Verification Authority to check and change the status of serialized medicine in the market.
 
Each manufacturer and parallel importer will be required to upload the Unique Identifier (UI) for each prescription medicine to the EMVS to enable (activate) them to be sold in Europe (commissioning process), which then will be automatically routed to the proper NMVS (National Medicine Verification System). Each NMVS repository will store the UIs of all active medicine within that given country.
 
The Antares Vision Decommissioning solution is designed to equip manufacturers, parallel importers, wholesalers, distributors, pharmacies and hospitals with a tool to easily communicate with the NMVO to verify, decommission or re-commission the products on their physical possession. It is available as a web-app for any mobile device or desktop stations. Furthermore, Antares Vision is linking the solution with semi-automatic and fully automatic systems, making the AV decommissioning solution the most complete available on the market.
 
This solution represents one step ahead in the comprehensive Antares Vision portfolio in pharmaceutical traceability, addressing the requirements of manufacturers and of several other stakeholders within the pharma supply chain.
Within the framework of the EU Falsified Medicines Directive – coming into force on February 9, 2019 – all operators involved with pharmaceuticals distribution must connect to the Medicine Verification Authority to check and change the status of serialized medicine in the market.

Each manufacturer and parallel importer will be required to upload the Unique Identifier (UI) for each prescription medicine to the EMVS to enable (activate) them to be sold in Europe (commissioning process), which then will be automatically routed to the proper NMVS (National Medicine Verification System). Each NMVS repository will store the UIs of all active medicine within that given country.

The Antares Vision Decommissioning solution is designed to equip manufacturers, parallel importers, wholesalers, distributors, with a tool to easily communicate with the NMVO to verify, decommission or re-commission the products on their physical possession. It is available as a web-app for any mobile device or desktop stations. Furthermore, Antares Vision is linking the solution with semi-automatic and fully automatic systems, making the AV decommissioning solution the most complete available on the market.

This solution represents one step ahead in the comprehensive Antares Vision portfolio in pharmaceutical traceability, addressing the requirements of manufacturers and of several other stakeholders within the pharma supply chain.
 
Quick, easy, ready to market! 
 
Need more information? Click here